Blood
Articles in this Issue
Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis
Abstract Background: There is a significant need for effective and well-tolerated therapies for patients (pts) with functional high-risk (FH...
ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C
Abstract Introduction: Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for adults with R/R MCL and R/R B-ALL. BL is a rare,...
Safety and efficacy of daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) in patients with multiple myeloma: A systematic review and meta-analysis.
Abstract Background Bortezomib, lenalidomide, and dexamethasone (VRd) remains a cornerstone in the treatment of multiple myeloma. Incorporat...
A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with persistent or chronic immune thrombocytopenia
Abstract Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a decreased platelet count due to accelerate...
Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia
Abstract Introduction Pediatric-inspired regimens have improved the survival of older adolescents and young adults (AYA)...
Somatic mutations and clinical outcomes in primary central nervous system lymphoma among hispanic and non-hispanic patients: A study from the University of California hematologic malignancies consortium (UCHMC)
Abstract Background: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive lymphoma characterized by...
Response dynamics to belumosudil in chronic graft-versus-host disease: Characterizing late responses and organ-specific response expectations from the rockstar study
Abstract Introduction: Chronic graft-versus-host disease (cGVHD) is a heterogenous, multiorgan complication of allogeneic hematopoietic cell...
Long-read whole genome sequencing improves clinical management in acute leukemia
Abstract Introduction Despite advances in molecular diagnosis of Acute Leukemia, current workflows often miss complex structural variants an...
Anemia and substance abuse-related mortality in older adults: A 24-year trend analysis in the US
Abstract Background: Anemia and Substance Abuse are rising public health concerns in the U.S., contributing greatly to cardiovascular compli...
Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy
Abstract INTRODUCTION T cell–redirecting therapies, including CAR T cells and bispecific antibodies (BsAbs), have transformed the treatment o...
Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study
Abstract Introduction: Despite significant advances, multiple myeloma (MM) remains largely incurable. The introduction of CD38-targeting age...
VTE management in primary central nervous system neoplasms : A retrospective cohort study in a Canadian tertiary center between 2013 and 2023
Abstract Background : Patients with primary central nervous system (CNS) neoplasms are at increased risk of venous thromboembolism (VTE) but...
Risk of lymphoma with antimetabolite and biologic combinations: A pharmacovigilance analysis using the FDA adverse event reporting system database
Abstract Background: Immunosuppressants and biologic agents are commonly used in the treatment of autoimmune and inflammatory conditions. An...
Risk factors and outcomes of carbapenem-resistant and multidrug-resistant klebsiella pneumoniae bloodstream infection in patients with acute leukemia
Abstract Background: Klebsiella pneumoniae bloodstream infection (KP-BSI) is a severe and potentially fatal complication in patients with ac...
Distinct prognosis and transplant timing in core-binding factor Acute Myeloid Leukemia
Abstract Introduction: Core binding factor acute myeloid leukemia (CBF-AML), defined by t(8;21)/RUNX1::RUNX1T1 or inv (16)/CBFβ::-MYH11, is...
A case of delayed transformation to lymphoid blast crisis in a patient with chronic myeloid leukemia
Abstract Late progression of Chronic Myeloid Leukemia (CML) to blast crisis is a rare event in the era of tyrosine kinase inhibitor (TKI) th...
Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis
Abstract Background: Treatment alternatives are scarce for patients with primary AL amyloidosis who have progressed following daratumumab- b...
Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups
Abstract Introduction The BIG-1 multicenter study was a prospective trial for younger AML patients with multiple randomizations at each stag...
Assessing replicability in chronic kidney disease severity scoring classifications using the sickle cell outcome grading system
Abstract Introduction The Sickle Cell Outcomes Grading System (SCOGS) is a disease severity grading system developed to...
Somatic mutation discovery in idiopathic multicentric castleman disease (iMCD) lymph node tissue identifies dysregulated intracellular calcium signaling as a potential disease mechanism and therapeutic target
Abstract Background: Idiopathic multicentric Castleman disease (iMCD) is a rare, atypical lymphoproliferative disorder with significant morb...
Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL
Abstract Background: Anti-CD19 chimeric antigen receptor T-cell therapy (CART) is an effective therapy for relapsed or refractory (R/R) larg...
Beyond survival in chronic myeloid leukemia: A systematic review of secondary malignancies in the era of tyrosine kinase inhibitors
Abstract Background: The introduction of tyrosine kinase inhibitors (TKIs) has markedly extended survival in chronic myeloid leukemia (CML),...
Prospective predictors of toxicity of BCMA‑directed CART therapy in multiple myeloma
Abstract Background: Anti–B cell maturation antigen (BCMA) chimeric antigen receptor T cell (CART) therapy has become a standard for relapse...
Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments
Abstract Introduction: Belamaf, a BCMA targeting antibody-drug conjugate (ADC), combined with standard therapies, demonstrated statistically...
Randomised Phase II study of acalabrutinib in combination with R-CHOP treatment for diffuse large B-cell lymphoma confirms safety and unimpaired treatment delivery
Abstract Introduction The phase Ib/II ACCEPT study (NCT03571308) assessed acalabrutinib (A), a second generation Bruton's tyrosine kinase in...